发明名称 |
Sustained release formulation of nalbuphine |
摘要 |
Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided. |
申请公布号 |
US9186330(B2) |
申请公布日期 |
2015.11.17 |
申请号 |
US201414319833 |
申请日期 |
2014.06.30 |
申请人 |
Endo Pharmaceuticals INC. |
发明人 |
Baichwal Anand R.;Goliber Philip A.;Carpanzano Anthony E.;Sciascia Thomas;Diehl, II Donald;Vogler Brian |
分类号 |
A61K9/20;A61K9/24;A61K31/485 |
主分类号 |
A61K9/20 |
代理机构 |
Davidson, Davidson & Kappel LLC |
代理人 |
Davidson, Davidson & Kappel LLC |
主权项 |
1. A sustained release oral solid dosage formulation comprising nalbuphine or a pharmaceutically acceptable salt thereof homogenously dispersed in a sustained release matrix delivery system, wherein the dosage form exhibits an in vitro dissolution of about 15% to about 50% by weight nalbuphine after 1 hour and at least about 65.3% by weight nalbuphine after 8 hours, and which provides a controlled release of nalbuphine over at least about 8 hours, in the form of a tablet. |
地址 |
Malvern PA US |